Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study. - Szepietowski JC; Reich A; Feldman SR; Pulka G; Mekokishvili L; Tsiskarishvili N; Svarca I; Poder A; Singh G; Deodhar S; Kumar K; Marwah A; et al. (Expert opinion on biological therapy, 2025)